

January 30, 2026

National Stock Exchange of India Limited
Exchange Plaza,
Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (E)
Mumbai – 400 051

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

Symbol: LALPATHLAB

Scrip Code: 539524

**Sub: Press Release on Un-audited Financial Results (Consolidated and Standalone)
for the Quarter & Nine Months ended December 31, 2025**

Dear Sir/ Madam,

Please find enclosed herewith the Press Release on the Un-audited Financial Results (Consolidated and Standalone) for the Quarter & Nine Months ended December 31, 2025.

We request you to please take the same on record.

Thanking You,
Yours Faithfully,

For Dr. Lal PathLabs Limited

Vinay Gujral
Company Secretary & Compliance Officer

Encl.: As above

Dr Lal PathLabs Limited records revenue of Rs 660 Cr in Q3 FY 2025-26

New Delhi, India, January 30, 2026 – Dr Lal PathLabs Limited (referred to as the “Company”; NSE: LALPATHLAB, BSE: 539524), a leading diagnostic and related healthcare service provider announces their financial results for the quarter ended December 31, 2025.

Consolidated Performance Highlights: Q3 FY26 vs Q3 FY25

- Revenue increased by 10.6% in Q3 FY26 and by 10.8% for nine months ended Dec’25
- EBITDA (before exceptional items) for Q3 FY26 increased by 16.3% with a margin of 27.2%
- P&L for Q3 FY26 includes an exceptional impact of Rs 30.1 Cr on account of Labour codes
- PAT for Q3 FY26 is Rs 91 Cr. with a margin for of 13.9%
- Interim Dividend of Rs. 3.5 per share for Q3 FY26
- Cash and Bank balances as on 31st Dec, 2025 is Rs. 1,411 Cr.

Financial Overview (Consolidated) in Rs Cr

Particulars	Q3			YTD		
	FY26	FY25	Gr %	FY26	FY25	Gr %
Revenue	660	597	10.6%	2060	1859	10.8%
Material consumed	129	117		399	364	
Employee benefit Expenses	135	126		399	367	
Fees to collection centres	96	87		294	264	
Other Expenses	121	112		372	337	
EBITDA before exceptional item	179	154	16.3%	596	527	13.1%
<i>Margins</i>	27.2%	25.8%		28.9%	28.3%	
Statutory impact of new Labour Codes	30	0		30	0	
EBITDA	149	154	-3.2%	566	527	7.4%
<i>Margins</i>	22.6%	25.8%		27.5%	28.3%	
Other Income	24	25		77	68	
Depreciation Cost	42	36		117	106	
Finance Cost	7	5		17	17	
PBT	124	138	-10.1%	509	471	8.0%
<i>Margins</i>	18.8%	23.2%		24.7%	25.4%	
PAT	91	98	-6.8%	378	337	12.2%
<i>Margins</i>	13.9%	16.4%		18.3%	18.1%	
EPS	5.4	5.8	-6.6%	22.4	20.0	12.2%



About Dr Lal PathLabs Limited

Dr Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. Through its' integrated, nationwide network, the company offer patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions.

As on March 31, 2025 the company has 298 clinical laboratories (including National Reference Lab at Delhi, Regional Reference Lab at Kolkata, Bangalore & Mumbai), 6,607 Patient Service Centers (PSCs) and 12,365 Pick-up Points (PUPs). Its' customers include individual patients, hospitals and other healthcare providers and corporate customers.

Contact Details

Ved Goel

Group Chief Financial Officer

Dr Lal PathLabs Limited

+91 124 3016500

cfo@lalpathlabs.com

Kritika Khatwani

Adfactors PR

+91 8604801332

kritika.khatwani@adfactorspr.com

For further information on Dr Lal PathLabs see www.lalpathlabs.com

Safe Harbour

This release contains statements that contain “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Dr Lal PathLabs future business developments and economic performance. While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macro-economic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance. Dr Lal PathLabs undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances.

Dr Lal Pathlabs Limited

12th Floor, Tower-B, SAS Tower, Sector-38, Medicity, Gurgaon 122001, Phone: +91 124 3016500, website: www.lalpathlabs.com